Glycomine has won FDA Breakthrough Therapy Designation for GLM101, an investigational substrate-replacement therapy for PMM2-CDG, the private San Carlos, California biotech announced 23 September 2026. PMM2-CDG is a rare, multisystem congenital disorder of glycosylation with no FDA-approved treatment; more than 90% of patients have ataxia. The designation rests on open-label Phase 2a data showing a mean 11.9-point improvement on a standard ataxia rating scale over 24 weeks in nine patients — a small, uncontrolled dataset that a placebo-controlled Phase 2b trial, already fully enrolled, is now built to confirm.
From San Carlos to a fully enrolled trial
GLM101's road from seed funding to a designation
- 2014
Glycomine founded
Founded in San Carlos, California to develop substrate-replacement therapies for congenital disorders of glycosylation.
- November 2016
$12M Series A
Led by Sanderling Ventures and Chiesi Ventures.
- 2019 – 2021
$68M Series B
Led by Abingworth and Sanofi Ventures, funding GLM101 into clinical trials.
- September 2024
FDA Fast Track Designation
GLM101's first FDA designation for PMM2-CDG.
- April 2025
$115M Series C
Led by CTI Life Sciences Fund, abrdn-managed funds and Advent Life Sciences, funding the Phase 2b POLAR trial.
- September 2025
POLAR Phase 2b dosing begins
First patient dosed in the global, randomized, placebo-controlled trial.
- April 2026
POLAR enrollment completed
43 patients enrolled across 15 sites globally.
- 23 September 2026
Breakthrough Therapy Designation
FDA grants Breakthrough Therapy Designation to GLM101 for PMM2-CDG.
- Q4 2026
POLAR topline data expected
Placebo-controlled data that would confirm or complicate the open-label Phase 2a signal.
An 11.9-point move on a 100-point scale
The Breakthrough Therapy Designation rests on an open-label Phase 2a study: nine adult and adolescent PMM2-CDG patients received weekly infusions of GLM101 and were scored on the International Cooperative Ataxia Rating Scale (ICARS), a 0-to-100 scale on which a higher score means worse impairment. After 24 weeks, the group's mean score improved by 11.9 points — a larger shift than the roughly 6-point, 25-week improvement Glycomine cites from published results with acetazolamide, an older drug sometimes used off-label. FDA reported no serious adverse events in the study; all adverse events were mild to moderate. An open-label study with nine patients and no control arm is not proof GLM101 works — it is the kind of early, promising signal Breakthrough Therapy Designation exists to accelerate toward a real answer, which is what the placebo-controlled POLAR trial is now designed to give.
“We are grateful to the patients, families, caregivers, and investigators who have made this work possible and look forward to sharing the results later this year.” Steven Axon, Chief Executive Officer, Glycomine — in the company's 23 September 2026 announcement
PMM2-CDG and GLM101, in four figures
Figures from Glycomine's own trial and funding disclosures. PMM2-CDG's global patient population is genuinely disputed in the literature, from roughly 800 diagnosed cases worldwide to a modeled estimate near 14,000 in North America and Europe combined — no single figure is printed here as settled.
Replacing a sugar the body can't build
PMM2-CDG is caused by mutations in the PMM2 gene, which encodes an enzyme needed for an early step in N-linked glycosylation — the process that attaches sugar chains to proteins throughout the body. Without a working enzyme, those sugar chains come out malformed, and the disease affects the nervous system, liver, immune system and more. GLM101 does not try to fix or chaperone the broken enzyme; it delivers mannose-1-phosphate, the metabolic product that enzyme would normally make, directly into cells inside a lipid nanoparticle, administered by weekly IV infusion. Because it works downstream of the specific mutation, Glycomine says the approach is designed to address the disease regardless of which of the many known PMM2 mutations a given patient carries.
Three things the designation does and doesn't change
A faster FDA review, not a market date
Breakthrough Therapy Designation gives Glycomine more frequent FDA interaction and eligibility for rolling review; it does not shorten GLM101's clinical trial timeline or guarantee the Phase 2b succeeds.
A first, but not alone
GLM101 is the first PMM2-CDG program to win Breakthrough Therapy Designation, but Maggie's Pearl's epalrestat, a repurposed small molecule, is already in Phase III for the same disease — a later clinical stage than GLM101's own Phase 2b.
A small study, honestly labelled
The 11.9-point ICARS improvement behind the designation comes from nine patients with no placebo arm. Glycomine's own next trial, POLAR, exists specifically because that kind of open-label signal isn't proof on its own.
A disease with zero approved drugs, one rival
There is no FDA-approved treatment for PMM2-CDG; care today is limited to managing symptoms — nutrition support, physical and occupational therapy, and treating complications as they arise. That leaves real room for a first approved therapy, but Glycomine is not developing in a vacuum. Maggie's Pearl, a joint venture of Perlara, Maggie's Cure and Mayo Clinic, has epalrestat — an oral drug originally developed for diabetic neuropathy, repurposed as a PMM2 enzyme activator — in a Phase III trial that closed enrollment in November 2023. Public reporting found no confirmed outcome from that trial beyond a March 2024 update transitioning remaining placebo patients to open-label dosing; its current status could not be independently confirmed for this article. A more distant comparison sits in Avalo Therapeutics' CERC-801/802/803 program, oral substrate-replacement therapies for three different, related congenital glycosylation disorders — not PMM2-CDG itself, but the same therapeutic approach applied elsewhere in the same rare-disease family.
GLM101 against PMM2-CDG's one other clinical-stage rival
| Program | Approach | Clinical stage |
|---|---|---|
| GLM101 (Glycomine) | Liposomal mannose-1-phosphate substrate replacement, weekly IV infusion | Phase 2b (POLAR), FDA Breakthrough Therapy Designation |
| Epalrestat (Maggie's Pearl) | Repurposed oral PMM2 enzyme activator | Phase III, enrollment closed Nov 2023 |
| Standard of care | Symptom management only | No approved drug exists |
From each program's own public trial disclosures; not a clinical comparison. Neither program is FDA-approved.
Rare enough that no market report prices it
$204.8B → $425.0B
Global rare disease therapeutics market, 2025 actual to 2034 forecast, per Fortune Business Insights (2025).
Sources: Fortune Business Insights, Rare Disease Treatment Market Size, Share & Industry Analysis · Grand View Research, Rare Disease Treatment Market Size & Share Report
Regulatory News outlook
No research publisher prices a PMM2-CDG-specific market — the disease is simply too rare, with published patient-count estimates ranging from a few hundred diagnosed cases worldwide to roughly 14,000 modeled across North America and Europe. Even at the high end of that range and U.S. ultra-orphan pricing norms, a first approved PMM2-CDG therapy would likely be a low-hundreds-of-millions-dollar product at peak, not a market-moving one — valuable to the patients it treats, immaterial to the broader rare-disease total above.
How we got here: Illustrative only: a few thousand treated patients globally at a plausible ultra-orphan annual price in the low-to-mid six figures per patient implies peak sales in the low hundreds of millions of dollars — not derived from any single publisher's PMM2-CDG-specific figure, because none exists.
The topline data that decides everything
Several facts about Glycomine itself are less settled than the company's regulatory record: its founding year is reported as both 2013 and 2014 across public sources, its current employee count is not reliably disclosed, and the specific quote used above, while consistent across the trade coverage found, could not be checked against Glycomine's own press release directly from this newsroom's research tools. None of that changes what actually happened on 23 September 2026 — a real FDA designation, on real if preliminary data. What happens next is the POLAR trial's placebo-controlled topline data, expected in the fourth quarter of 2026, which will either confirm the open-label signal behind this designation or complicate it.
Sources & further reading
- BioPharm International, “FDA Grants Breakthrough Therapy Designation to Glycomine's GLM101 for PMM2-CDG,” 23 September 2026. biopharminternational.com
- Glycomine, “Glycomine Completes Enrollment in Global Phase 2b POLAR Study of GLM101 for the Treatment of PMM2-CDG,” press release, April 2026. businesswire.com
- Glycomine, “Glycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate GLM101 into a Phase 2b Clinical Trial for PMM2-CDG,” press release, 16 April 2025. businesswire.com
- ClinicalTrials.gov, “A Study to Assess the Efficacy and Safety of Weekly Doses of GLM101 in Participants With PMM2-CDG” (POLAR, NCT06892288). clinicaltrials.gov
- BioSpace, “Maggie's Pearl Initiates Phase III Clinical Trial for Treatment of Patients With PMM2-CDG.” biospace.com
- ClinicalTrials.gov, epalrestat Phase III trial record (NCT04925960). clinicaltrials.gov
- Avalo Therapeutics (Cerecor), “FDA Grants Cerecor's Three Substrate Replacement Therapies Orphan Drug Designation.” ir.avalotx.com
- Fortune Business Insights, Rare Disease Treatment Market Size, Share & Industry Analysis. fortunebusinessinsights.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
What did FDA grant Glycomine?
Breakthrough Therapy Designation, announced 23 September 2026, for GLM101, an investigational liposomal mannose-1-phosphate substrate-replacement therapy for PMM2-CDG, a rare congenital disorder of glycosylation. The designation speeds FDA's review; GLM101 has not been approved and remains in clinical trials.
What is PMM2-CDG?
A rare, inherited disorder caused by mutations in the PMM2 gene, which is needed for an early step in building the sugar chains (glycans) that proteins throughout the body depend on. More than 90% of patients have ataxia, and the disease affects multiple organ systems. No treatment is currently FDA-approved; care is limited to managing symptoms.
Is GLM101 the only drug in development for PMM2-CDG?
No. Maggie's Pearl, a joint venture of Perlara, Maggie's Cure and Mayo Clinic, has epalrestat, a repurposed oral drug, in a Phase III trial for PMM2-CDG — a later clinical stage than GLM101's Phase 2b. GLM101 is, however, the first PMM2-CDG program to win FDA Breakthrough Therapy Designation.
Is Glycomine publicly traded?
No. It is a private, venture-backed biotech headquartered in San Carlos, California, founded around 2014. It has raised roughly $195 million across six funding rounds, most recently a $115 million Series C in April 2025.
